Evidence map›Paper›PMID 28850612›Full record

ArticlePloS one2017

An application of competitive reporter monitored amplification (CMA) for rapid detection of single nucleotide polymorphisms (SNPs).

Juliane Havlicek, Eric Rivera-Milla, Peter Slickers, Sönke Andres, Silke Feuerriegel, Stefan Niemann, Matthias Merker, Ines Labugger

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Juliane HavlicekAlere Technologies GmbH, Jena, Germany.
Eric Rivera-MillaAlere Technologies GmbH, Jena, Germany.
Peter SlickersAlere Technologies GmbH, Jena, Germany.
Sönke AndresNational Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany.
Silke FeuerriegelMolecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Stefan NiemannMolecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Matthias MerkerMolecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.ORCID http://orcid.org/0000-0003-1386-2331
Ines LabuggerAlere Technologies GmbH, Jena, Germany.
Alere (Germany) · DEResearch Center Borstel - Leibniz Lung Center · DEGerman Center for Infection Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single nucleotide polymorphisms (SNPs) are essential parameters in molecular diagnostics and can be used for the early detection and clinical prognosis in various diseases. Available methods for SNP detection are still labor-intensive and require a complex laboratory infrastructure, which are not suitable for the usage in resource-limited settings. Thus, there is an urgent need for a simple, reliable and rapid approach. In this paper we modified the previously developed competitive reporter monitored amplification (CMA) technique for the detection of resistance mediating SNPs in Mycobacterium tuberculosis complex (MTBC) strains. As a proof-of-principle for the application of the CMA-based SNP assay in routine molecular tuberculosis diagnostic, we show that the assay recognizes resistance mediating SNPs for rifampicin, isoniazid and ethambutol from either isolated DNA or heat inactivated M. tuberculosis cell cultures. The CMA-based SNP assay can identify the most prevalent resistance mediating mutations in the genes rpoB, katG, embB, and the promotor region of inhA within one hour.

Indexed as

Genes, ReporterPolymorphism, Single NucleotideAntitubercular AgentsDrug Resistance, BacterialEthambutolHumansIsoniazidMolecular Diagnostic TechniquesMycobacterium tuberculosisRifampinTuberculosisAntitubercular AgentsEthambutolIsoniazidRifampin

Identifiers

PMID28850612
PMCPMC5574540
OpenAlexW2751059391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.